The start-up Imisca and Erganeo have signed an exclusive licence for the exploitation of a new gel-forming solution to reduce the recurrence rate after local treatment of colorectal cancer.
On 2 June 2023, Summit Pharmaceuticals International, a biopharmaceutical company, and start-up EVerZom signed an exclusive distribution agreement in Japan.
The start-up, IPCure, and Erganeo have signed a licence agreement for the exclusive exploitation of a new type of compounds for the treatment of certain diseases with an inflammatory component.
Revenir à une stratégie de valorisation plus large, en recentrant son activité sur la maturation et le transfert vers tous les acteurs économiques, renforcer les relations avec les établissements et l’écosystème et améliorer sa performance et son efficience.
En octobre 2022, Naceur Tounekti a été nommé président d’Erganeo pour déployer une nouvelle feuille de route.
After signing a research collaboration agreement with the APHP, start-up Augmented Endoscopy and Erganeo have signed an exclusive license for the exploitation of the Axaro.ai solution.
Erganeo and METHYS Dx announce news of an exclusive licensing agreement for the use of diagnostic biomarkers via liquid biopsy.
Sylvie Retailleau, French Minister of Higher Education and Research, unveiled the list of 17 winners of the France 2030 call for "maturation - prematuration" projects, including 9 consortia with Erganeo.
Sylvie Retailleau, Minister for Higher Education and Research, and her counterpart Roland Lescure, Minister for Industry, unveiled the names of the winners of the France 2030 "maturation-pre-maturation" AAP.
An exclusive license was signed on 10 November, 2022, between Erganeo and the start-up Persea, for development of a new treatment for liver cancer.